Scienture Holdings Inc (SCNX)

Currency in USD
0.370
+0.037(+11.11%)
Closed·
0.331-0.039(-10.54%)
·
Unusual Post-Market activity
Unusual trading volume
SCNX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.3350.385
52 wk Range
0.2382.600
Key Statistics
Prev. Close
0.333
Open
0.352
Day's Range
0.335-0.385
52 wk Range
0.238-2.6
Volume
46.71M
Average Volume (3m)
1.49M
1-Year Change
-76.7233%
Book Value / Share
1.64
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SCNX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.500
Upside
+305.41%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Scienture Holdings Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1.500
(+305.41% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Buy1.50+305.41%-New CoverageFeb 24, 2026

Earnings

Latest Release
May 18, 2026
EPS / Forecast
-0.08 / --
Revenue / Forecast
56.33K / --
EPS Revisions
Last 90 days

SCNX Income Statement

Compare SCNX to Peers and Sector

Metrics to compare
SCNX
Peers
Sector
Relationship
P/E Ratio
−0.4x−0.3x−0.4x
PEG Ratio
−0.01−0.010.00
Price/Book
0.2x0.9x2.6x
Price / LTM Sales
31.5x0.7x3.0x
Upside (Analyst Target)
305.4%50.6%51.5%
Fair Value Upside
Unlock42.7%8.8%Unlock

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.

Employees
7

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
968.91K2.38%358.60K
Other Institutional Investors
2.90M7.14%1.07M
Public Companies & Retail Investors
36.76M90.47%13.60M
Total
40.63M100.00%15.04M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
L1 Capital Global Opportunities Master Fund, Ltd.2.65%1,075,000398
L1 Global Manager Pty Ltd2.65%1,075,000398

People Also Watch

1.590
GDC
-1.85%
8.1100
YYAI
+11.25%
0.2927
COSM
+12.02%
3.180
ESPR
-0.31%
0.335
MREO
+3.39%

FAQ

What Is the Scienture Holdings (SCNX) Stock Price Today?

The Scienture Holdings stock price today is 0.370 USD.

What Stock Exchange Does Scienture Holdings Trade On?

Scienture Holdings is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Scienture Holdings?

The stock symbol for Scienture Holdings is "SCNX."

What Is the Scienture Holdings Market Cap?

As of today, Scienture Holdings market cap is 15.040M USD.

What Is Scienture Holdings's Earnings Per Share (TTM)?

The Scienture Holdings EPS (TTM) is -1.808.

When Is the Next Scienture Holdings Earnings Date?

Scienture Holdings will release its next earnings report on Aug 17, 2026.

From a Technical Analysis Perspective, Is SCNX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Scienture Holdings Stock Split?

Scienture Holdings has split 4 times.

How Many Employees Does Scienture Holdings Have?

Scienture Holdings has 7 employees.

What is the current trading status of Scienture Holdings (SCNX)?

As of Jul 13, 2026, Scienture Holdings (SCNX) is trading at a price of 0.370 USD, with a previous close of 0.333 USD. The stock has fluctuated within a day range of 0.335 USD to 0.385 USD, while its 52-week range spans from 0.238 USD to 2.600 USD.

What Is Scienture Holdings (SCNX) Price Target According to Analysts?

The average 12-month price target for Scienture Holdings is 1.500 USD, with a high estimate of 1.5 USD and a low estimate of 1.5 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +305.41% Upside potential.

What Is the SCNX Premarket Price?

SCNX's last pre-market stock price is 0.352 USD. The pre-market share volume is 36,450,000.000, and the stock has decreased by 0.019, or 5.710%.

What Is the SCNX After Hours Price?

SCNX's last after hours stock price is 0.331 USD, the stock has decreased by -0.039, or -10.540%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.